Braveheart Bio Inc. (BRVE)
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BRVE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.67B
- EPS (TTM)
- -$5.70
- Dividend yield
- None
- 52-week range
- 18.47 – 32.00
- Day range
- 18.47 – 19.65
- Volume / Avg
- 336.95K / 567.47K
- Beta
- —
- Shares outstanding
- 90.04M
- Next earnings
- Nov 12, 2026
52-week range
BRVE stock today
Shares of Braveheart Bio (BRVE) finished lower on Oct 7 at $18.58, a drop of 6.11% or $1.21 per share, versus the S&P 500's 0.22% decline. Shares are 41.9% below their 52-week high of $32.00, set on Aug 7, 2026 and 0.6% above the 52-week low of $18.47, near the bottom of the past year's range. Braveheart Bio has posted a net loss over the last twelve months (EPS of -$5.70), so its P/E ratio is not meaningful.
Braveheart Bio's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Braveheart Bio
Company profileBraveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Travis Murdoch B.S., M.D., M.Sc.
- Headquarters
- San Francisco, CA
- Employees
- 49
- IPO year
- 2026
- Website
- braveheart.bio
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$45.25+143.54%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 12, 2026
Braveheart Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SEPNSepterna Inc. | 36.00 | +0.93% | $1.68B | vs BRVE |
| ANIPANI Pharmaceuticals Inc. | 71.93 | +0.57% | $1.65B | vs BRVE |
| NUVBNuvation Bio Inc. Class A | 4.86 | -0.41% | $1.71B | vs BRVE |
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.69 | +1.12% | $1.62B | vs BRVE |
| QUREuniQure N.V. | 23.14 | +0.35% | $1.61B | vs BRVE |
| GENBGenerate Biomedicines Inc. | 13.57 | -1.67% | $1.74B | vs BRVE |
| OCULOcular Therapeutix Inc. | 7.23 | -1.50% | $1.59B | vs BRVE |
| ETONEton Pharmaceuticals Inc. | 54.88 | +0.20% | $1.57B | vs BRVE |
Indexes, lists and sector
Braveheart Bio stock FAQ
What is Braveheart Bio's stock price today?
BRVE last traded at $18.58 as of Oct 7, 4:00 PM EDT, down 6.11% on the day. Prices are delayed at least 15 minutes.
When is Braveheart Bio's next earnings date?
Braveheart Bio is expected to report earnings on Thursday, November 12, 2026.
Who is Braveheart Bio's CEO?
Dr. Travis Murdoch B.S., M.D., M.Sc. is the chief executive officer of Braveheart Bio Inc., which has about 49 employees.
What is the BRVE 52-week high?
The 52-week high for BRVE is $32.00 and the 52-week low is $18.47. The stock is currently 41.9% below its high.